Role of Proteomics in Diagnosis of Cancer

被引：13

作者：

Jain, K. K. ^{[1
]}

机构：

[1] Jain PharmaBiotech, CH-4057 Basel, Switzerland

来源：

TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2002年 / 1卷 / 04期

关键词：

molecular diagnosis; proteomics; cancer diagnosis; proteodiagnostics; biomarkers;

D O I：

10.1177/153303460200100409

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Proteomic technologies have emerged as an important addition to the genomic and antibody-based technologies for the diagnosis of cancer. Important technologies include 2-D gel electrophoresis, mass spectrometry, laser capture microdissection, detection of molecular markers of cancer and protein patterns. For clinical applications, the most likely technologies to be used widely are protein biochips. Application of these technologies to various cancers are described. Proteomic technologies have a potential in developing molecular diagnostics and markers for the early detection of cancer. However, information from various diagnostic technologies should be integrated to obtain the optimal information required for clinical management of a patient.

引用

页码：281 / 286

页数：6

共 27 条

[1] Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles [J].

Alaiya, AA ;

Franzén, B ;

Hagman, A ;

Dysvik, B ;

Roblick, UJ ;

Becker, S ;

Moberger, B ;

Auer, G ;

Linder, S .

INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (06) :895-899

[2] An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer [J].

Brichory, FM ;

Misek, DE ;

Yim, AM ;

Krause, MC ;

Giordano, TJ ;

Beer, DG ;

Hanash, SM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (17) :9824-9829

[3]

Brünagel G, 2002, CANCER RES, V62, P2437

[4]

Burchardt M, 2000, CLIN CHEM, V46, P595

[5]

Celis JE, 2000, ELECTROPHORESIS, V21, P2115

[6]

Emmert-Buck MR, 2000, MOL CARCINOGEN, V27, P158, DOI 10.1002/(SICI)1098-2744(200003)27:3<158::AID-MC2>3.0.CO

[7]

2-2

[8]

Fung ET, 2000, CURR OPIN MOL THER, V2, P643

[9]

Jain K. K, 2002, MOL DIAGNOSTICS TECH

[10]

Jain KK, 2002, CURR OPIN MOL THER, V4, P203

← 1 2 3 →